Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Zydus Therapeutics Inc."
Count: 15
Selected: 0
NCT06427395Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
NCT05133336Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
NCT04446507A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function
NCT05011305Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
NCT03863574Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
NCT03112681Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
NCT03061721Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
NCT05211284Saroglitazar Magnesium 4 mg for NASH in People Living With HIV in the US
NCT05045482Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
NCT04469920Hepatic Impairment, Cholestatic Liver Disease, & NASH With Advanced Fibrosis & Normal Hepatic Function
NCT03639623Safety, Tolerability and Efficacy of Saroglitazar Mg 4 mg in Liver Transplant Recipients With NAFLD
NCT03617263Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)
NCT03097107Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL
NCT04045769A Study to Evaluate the Effect of Saroglitazar Magnesium on the QTc Interval in Healthy Volunteers
NCT04112446Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects